Pulmonary arterial hypertension associated with congenital heart disease

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Jun 1989

Epogen: FDA approved

Treatment of anemia associated with chronic renal failure, including patients on dialysis (end stage renal disesae) and patients not on dialysis

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Pulmonary arterial hypertension associated with congenital heart disease.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Epogen

(Epoetin alfa)Orphan drug

Amgen, Inc.

12.1 Mechanism of Action Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.

Approved Jun 1989FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Pulmonary arterial hypertension associated with congenital heart disease.
Search all trials →
Search clinical trials for Pulmonary arterial hypertension associated with congenital heart disease

Recent News & Research

No recent news articles indexed yet for Pulmonary arterial hypertension associated with congenital heart disease.
Search PubMed for Pulmonary arterial hypertension associated with congenital heart disease

Browse all Pulmonary arterial hypertension associated with congenital heart disease news →

Specialist Network

Top 6 by expertise

View all Pulmonary arterial hypertension associated with congenital heart disease specialists →

Quick Actions